DEFA14A: Alkermes Boosts Avadel Buyout Offer to $22.50/Share

Alkermes plc has increased its recommended offer to acquire Avadel Pharmaceuticals plc to up to $22.50 per share, a move prompted by a competing proposal from H. Lundbeck A/S.

Summary

• Alkermes plc has increased its offer to acquire Avadel Pharmaceuticals plc to a total consideration of up to $22.50 per Avadel share.
• The revised offer consists of $21.00 in cash per share and one non-transferable contingent value right (CVR) entitling holders to a potential additional cash payment of $1.50 per share.
• The CVR payment is contingent upon final U.S. Food and Drug Administration (FDA) LUMRYZ Approval for the treatment of idiopathic hypersomnia in adults by the end of 2028.
• The increased offer values Avadel at up to approximately $2.37 billion, assuming the CVR milestone is achieved.
• Avadel's board of directors unanimously recommends the increased offer, determining it to be superior to a competing proposal from H. Lundbeck A/S, particularly due to the CVR terms.
• The acquisition is expected to close in the first quarter of 2026.

Sentiment

Score: 9

Explanation: The increased offer price, unanimous board recommendation, and favorable comparison to a competing bid indicate a highly positive outcome for Avadel shareholders. The secured financing and strategic rationale further strengthen the positive sentiment, despite the contingent nature of the CVR.

Positives

• The cash consideration per Avadel share increased from $18.50 to $21.00, representing a significant uplift for shareholders.
• Avadel's board of directors unanimously recommends the increased offer, indicating strong internal support.
• The CVR terms from Alkermes were deemed superior to those in a competing proposal from Lundbeck, which were considered unlikely to be achieved.
• Alkermes has secured fully underwritten financing commitments of approximately $1.5 billion from JPMorgan Chase Bank, N.A., ensuring funding for the cash portion of the acquisition.
• The acquisition is expected to maximize the value of Avadel's LUMRYZ product and accelerate its global reach, leveraging Alkermes' commercial scale and R&D capabilities.

Negatives

• The CVR payment of $1.50 per share is contingent and not guaranteed, dependent on FDA approval of LUMRYZ for idiopathic hypersomnia by December 31, 2028.
• The maximum reimbursement payable by Avadel to Alkermes if the transaction is terminated under certain circumstances (e.g., a superior proposal) increased from $19.3 million to $22.1 million.

Risks

• The ability of the parties to consummate the acquisition in a timely manner or at all, including obtaining shareholder and regulatory approvals.
• The possibility that competing offers for Avadel may still be made.
• Potential delays in consummating the acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition.
• The impact of health pandemics on the parties' respective businesses.
• The occurrence of any event, change, or circumstance that could lead to the termination of the Amended Transaction Agreement.
• The effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results, and business generally.
• Costs related to the acquisition.
• The outcome of any legal proceedings that may be instituted against the parties related to the Amended Transaction Agreement or the acquisition.
• Clinical development activities may not be initiated or completed on expected timelines or at all.
• Results of development activities may not be positive or predictive of future results.
• Products or product candidates could be shown to be ineffective or unsafe.
• FDA or other regulatory authorities may not agree with regulatory approval strategies or may make adverse decisions.
• Inability to successfully commercialize products or support revenue growth.
• Reduction in payment rate or reimbursement for products or an increase in related financial obligations to government payers.
• Products may prove difficult to manufacture, be precluded from commercialization by third-party proprietary rights, or have unintended side effects, adverse reactions, or incidents of misuse.

Future Outlook

The acquisition is expected to close in the first quarter of 2026, subject to shareholder and regulatory approvals. Alkermes anticipates maximizing the value of Avadel's LUMRYZ product and accelerating its global reach by leveraging Alkermes' commercial scale and enhanced R&D and technology capabilities. The combined entity aims to advance the pipeline to develop more therapies for underserved patients.

Management Comments

• Avadel's board of directors determined that the Lundbeck Proposal no longer constituted a Company Superior Proposal, as the upfront cash consideration was identical, but the terms of the CVR in Alkermes' Increased Offer were superior and more likely to be achieved.
• The Company Board believes Alkermes has the capacity to maximize the value of Avadel's current portfolio and accelerate the ability for LUMRYZ to reach more patients globally with increased global commercial scale as well as enhanced R&D and technology capabilities to rapidly advance the pipeline to develop more therapies for patients who are underserved.
• The Avadel Board intends to unanimously recommend to the Company Shareholders to vote in favor of the Scheme Meeting Resolution and the Required EGM Resolutions.

Industry Context

This acquisition highlights the ongoing consolidation and strategic M&A activity within the biopharmaceutical sector, particularly for companies with promising commercial products like Avadel's LUMRYZ. Alkermes, a global biopharmaceutical company focused on neuroscience, is expanding its portfolio and market presence by acquiring Avadel, which specializes in transforming medicines for conditions like narcolepsy. The competitive bid from H. Lundbeck A/S underscores the high value placed on Avadel's assets and pipeline within the industry.

Comparison to Industry Standards

• The increased offer from Alkermes of $21.00 cash plus a $1.50 CVR (total $22.50) directly compares to the unsolicited proposal from H. Lundbeck A/S of $21.00 cash plus a CVR of up to $2.00 (based on sales milestones of $450M by 2027 and $700M by 2030).
• Avadel's board determined Alkermes' CVR terms were superior because Lundbeck's CVR was deemed 'unlikely to be achieved,' suggesting Alkermes' CVR, tied to FDA approval for idiopathic hypersomnia by 2028, is perceived as more attainable or valuable.
• The total transaction value of up to $2.37 billion for Avadel reflects a significant valuation for a company with a key commercial product (LUMRYZ for narcolepsy) and potential pipeline expansion into related indications (idiopathic hypersomnia).

Corporate Governance

Legal Proceedings

• The filing mentions the possibility of legal proceedings being instituted against the parties or their directors/officers related to the Amended Transaction Agreement or the acquisition.

Stakeholder Impact

• Shareholders: Will receive an increased cash consideration and a CVR, with the Avadel board unanimously recommending the offer.
• Employees: Potential for integration challenges and changes in management/operations post-acquisition, though not explicitly detailed.
• Customers/Patients: The acquisition aims to accelerate LUMRYZ's global reach and advance the pipeline, potentially benefiting patients with narcolepsy and idiopathic hypersomnia.
• Creditors: Alkermes has secured significant financing, indicating a stable financial plan for the acquisition.

Next Steps

• Avadel intends to file a definitive proxy statement with the SEC related to the acquisition.
• Shareholder meetings (Scheme Meeting and EGM) will be held to approve the acquisition.
• The parties will continue to seek necessary regulatory approvals (Clearances under HSR Act and other Antitrust Laws).
• The acquisition is expected to close in the first quarter of 2026.

Key Dates

Recommendation

The increased cash offer of $21.00 per share, combined with a CVR of $1.50, represents a substantial premium and a highly favorable outcome for Avadel shareholders. The unanimous recommendation by Avadel's board, after evaluating a competing superior proposal, underscores the attractiveness of this revised offer. The secured financing by Alkermes provides confidence in the deal's completion. For Avadel shareholders, accepting this offer appears to be the optimal path to realize significant value.

Keywords

Acquisition, Biopharmaceutical, Merger, Contingent Value Right, CVR, LUMRYZ, Narcolepsy, Idiopathic Hypersomnia, FDA Approval, Alkermes, Avadel, M&A